PE20151524A1 - FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE - Google Patents
FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTEInfo
- Publication number
- PE20151524A1 PE20151524A1 PE2015000925A PE2015000925A PE20151524A1 PE 20151524 A1 PE20151524 A1 PE 20151524A1 PE 2015000925 A PE2015000925 A PE 2015000925A PE 2015000925 A PE2015000925 A PE 2015000925A PE 20151524 A1 PE20151524 A1 PE 20151524A1
- Authority
- PE
- Peru
- Prior art keywords
- hum13b8
- genetically manipulated
- solution formulations
- antibody
- antibodies solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737035P | 2012-12-13 | 2012-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151524A1 true PE20151524A1 (es) | 2015-11-06 |
Family
ID=50934859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000925A PE20151524A1 (es) | 2012-12-13 | 2013-12-09 | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| JP7179717B2 (ja) * | 2017-03-31 | 2022-11-29 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法 |
| MX2020009265A (es) * | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
| SG11202104166QA (en) * | 2018-11-21 | 2021-05-28 | Regeneron Pharma | High concentration protein formulation |
| CN112334483B (zh) | 2018-11-27 | 2022-05-10 | 信达生物制药(苏州)有限公司 | 抗IL-23p19抗体及其用途 |
| US12493019B2 (en) | 2019-02-20 | 2025-12-09 | Amgen Inc. | Methods of determining protein stability |
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| US11396541B2 (en) | 2019-12-20 | 2022-07-26 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 P19 antibodies and methods of use thereof |
| BR112022022919A2 (pt) * | 2020-05-13 | 2022-12-20 | Innovent Biologics Suzhou Co Ltd | Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo". |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2025071362A1 (ko) * | 2023-09-27 | 2025-04-03 | 삼성바이오에피스 주식회사 | 항-il-23 항체의 안정한 액상 제형 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2366706A1 (en) | 1999-03-11 | 2000-09-14 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| JP4505166B2 (ja) | 1999-09-09 | 2010-07-21 | シェーリング コーポレイション | 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用 |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| DK2236154T3 (en) | 2003-02-10 | 2018-06-25 | Biogen Ma Inc | IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT |
| EP1601694B1 (en) | 2003-03-10 | 2009-08-26 | Schering Corporation | Uses of il-23 antagonists; related reagents |
| BRPI0403964B8 (pt) * | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| WO2005079837A1 (en) | 2004-02-17 | 2005-09-01 | Schering Corporation | Methods of modulating il-23 activity; related reagents |
| WO2005117967A2 (en) | 2004-04-12 | 2005-12-15 | Medimmune, Inc. | Anti-il-9 antibody formulations and uses thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| HRP20130400T1 (en) | 2005-06-30 | 2013-06-30 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| DK1931710T3 (en) | 2005-08-31 | 2017-04-03 | Merck Sharp & Dohme | CONSTRUCTED ANTI-IL-23 ANTIBODIES |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| MX2009003982A (es) | 2006-10-20 | 2009-04-27 | Amgen Inc | Formulaciones de polipeptido estables. |
| AU2008204901A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| US8293883B2 (en) * | 2007-02-23 | 2012-10-23 | Schering Corporation | Engineered anti-IL-23P19 antibodies |
| EP2068923A4 (en) * | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| WO2009114040A2 (en) | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009288419B2 (en) * | 2008-08-27 | 2015-08-06 | Merck Sharp & Dohme Llc | Lyophilized formulatons of engineered anti-IL-23p19 antibodies |
| EP2331090B1 (en) * | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
| WO2010062896A1 (en) * | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| KR20120110175A (ko) * | 2009-12-29 | 2012-10-09 | 에프. 호프만-라 로슈 아게 | 항체 제제 |
| DK2691112T3 (en) | 2011-03-31 | 2018-07-30 | Merck Sharp & Dohme | STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS |
-
2013
- 2013-09-12 UA UAA201506824A patent/UA117466C2/uk unknown
- 2013-12-09 IL IL278295A patent/IL278295B2/en unknown
- 2013-12-09 PT PT13863590T patent/PT2931313T/pt unknown
- 2013-12-09 NZ NZ708443A patent/NZ708443A/en unknown
- 2013-12-09 CA CA2894869A patent/CA2894869C/en active Active
- 2013-12-09 KR KR1020157018314A patent/KR102004585B1/ko active Active
- 2013-12-09 CN CN201380065606.7A patent/CN104870016B/zh active Active
- 2013-12-09 DK DK13863590.9T patent/DK2931313T3/da active
- 2013-12-09 TR TR2019/09584T patent/TR201909584T4/tr unknown
- 2013-12-09 BR BR112015013540-4A patent/BR112015013540B1/pt active IP Right Grant
- 2013-12-09 MX MX2015007213A patent/MX357936B/es active IP Right Grant
- 2013-12-09 LT LTEP13863590.9T patent/LT2931313T/lt unknown
- 2013-12-09 WO PCT/US2013/073825 patent/WO2014093203A1/en not_active Ceased
- 2013-12-09 MY MYPI2015701965A patent/MY187921A/en unknown
- 2013-12-09 SM SM20190414T patent/SMT201900414T1/it unknown
- 2013-12-09 PE PE2015000925A patent/PE20151524A1/es active IP Right Grant
- 2013-12-09 AU AU2013359767A patent/AU2013359767B2/en active Active
- 2013-12-09 SI SI201331504T patent/SI2931313T1/sl unknown
- 2013-12-09 PL PL13863590T patent/PL2931313T3/pl unknown
- 2013-12-09 JP JP2015547448A patent/JP6266012B2/ja active Active
- 2013-12-09 RS RS20190822A patent/RS59057B1/sr unknown
- 2013-12-09 HU HUE13863590A patent/HUE045668T2/hu unknown
- 2013-12-09 EA EA201591133A patent/EA034616B1/ru unknown
- 2013-12-09 EP EP13863590.9A patent/EP2931313B1/en active Active
- 2013-12-09 ES ES13863590T patent/ES2732861T3/es active Active
- 2013-12-09 HR HRP20191137TT patent/HRP20191137T1/hr unknown
- 2013-12-09 IL IL307581A patent/IL307581A/en unknown
-
2015
- 2015-06-02 IL IL239150A patent/IL239150B/en active IP Right Grant
- 2015-06-08 PH PH12015501296A patent/PH12015501296A1/en unknown
- 2015-06-10 CL CL2015001608A patent/CL2015001608A1/es unknown
- 2015-06-18 ZA ZA2015/04408A patent/ZA201504408B/en unknown
-
2019
- 2019-06-27 CY CY20191100675T patent/CY1121895T1/el unknown
-
2020
- 2020-12-08 US US17/114,754 patent/US20210188964A1/en active Pending
-
2024
- 2024-01-05 US US18/405,772 patent/US20240239884A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| PE20181790A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| AR092400A1 (es) | Formulaciones de anticuerpos y proteinas de alta concentracion | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| PE20170948A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| PE20191242A1 (es) | Formulaciones de anticuerpo y metodos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| CL2013003146A1 (es) | Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria. | |
| CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |